AMD progression linked to carbohydrates

Article

Patients at risk of advanced age-related macular degeneration (AMD) progression may benefit from consuming a smaller amount of refined carbohydrates.

Patients at risk of advanced age-related macular degeneration (AMD) progression may benefit from consuming a smaller amount of refined carbohydrates, according to a study published in the October issue of the American Journal of Clinical Nutrition.

Chung-Jung Chiu and fellow researchers colleagues from Tufts University, Boston, The AREDS Co-ordinating Center, EMMES Corporation and the University of Wisconsin, USA prospectively evaluated the effect of baseline dietary glycemic index (dGI) on the progression of AMD.

dGI was calculated as the weighted average of GIs from foods and was evaluated as being above or below the sex median (women: 77.9; men: 79.3) for 3,977 participants in the Age-Related Eye Disease Study (AREDS) aged between 55 and 80 years. The 7,232 eyes without advanced AMD were classified into one of three AMD categories: Group 1 (non-extensive small drusen), Group 2 (intermediate drusen) and Group 3 (large drusen or pigmentary abnormalities). Multi-failure Cox proportional-hazards regression was used to model the time to the maximal progression in order to evaluate the relationship between dGI and the risk of AMD.

The multivariate-adjusted risk of progression over the eight-year follow-up period was significantly higher in the high-dGI group than in the low dGI group. The risk of progression for groups 1, 2 and 3 was 5%, 8% and 17% greater, respectively. The latter gives an estimate that 7.8% of new advanced AMD patients could be prevented if people consumed a low-dGI diet.

The researchers believe that patients at risk of AMD progression, especially those at a high risk of advanced AMD, could benefit from consuming less refined carbohydrates.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.